Lilly has unveiled promising results from a Phase III study of a lung cancer treatment which showed improved overall survival in patients. The news is a welcome relief to Lilly, which has endured a ...

Eli Lilly and Company’s LLY announced that a late-stage study evaluating its already approved cancer drug, Cyramza for the second-line treatment of liver cancer met the primary as well as secondary ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s Verzenio has proven it can extend patients’ lives in the indication. Verzenio ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...